UMass RPGR Gene Therapy Patent US12606825B2
Summary
The USPTO granted patent US12606825B2 to University of Massachusetts covering compositions and methods for modulating RPGR (retinitis pigmentosa GTPase regulator) expression for treating retinitis pigmentosa. The patent includes expression vectors encoding RPGR proteins and inhibitory nucleic acids targeting RPGRCONST isoforms. The application was filed on March 4, 2021, with 16 claims granted.
What changed
The USPTO issued patent US12606825B2 to University of Massachusetts for compositions and methods related to RPGR expression modulation in treating retinitis pigmentosa. The patent covers expression vectors encoding RPGR proteins and inhibitory nucleic acids targeting RPGRCONST isoforms. This grant provides UMass with exclusive rights to these therapeutic compositions and treatment methods.
Entities developing gene therapies targeting RPGR for retinitis pigmentosa should review this patent for potential freedom-to-operate or licensing considerations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for modulating RPGR expression
Grant US12606825B2 Kind: B2 Apr 21, 2026
Assignee
University of Massachusetts
Inventors
Hemant Khanna, Laura Moreno Leon
Abstract
Aspects of the disclosure relate to compositions and methods for modulating expression of certain RPGR retinitis pigmentosa GTPase regulator (RPGR) proteins in a cell or subject. In some embodiments the disclosure provides expression vectors encoding one or more RPGR proteins and/or one or more inhibitory nucleic acids that target certain isoforms of RPGR, for example RPGRCONST. In some aspects, the disclosure relates to methods of treating retinitis pigmentosa (RP) in a subject by administering compositions that modulate RPGR expression or activity.
CPC Classifications
C12N 15/113 C12N 2310/141
Filing Date
2021-03-04
Application No.
17909148
Claims
16
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.